Drug Trial Radar · NCT06242470
A Study of MGC026 in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
394
Planned (sponsor's estimate)
Start
Mar 6, 2024
Primary completion
Oct 2028
Study completion Apr 2029
Sponsor
- Lead sponsor
- MacroGenicsIndustry
- Sponsor type
- Industry
- First posted
- Feb 5, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable, locally advanced or metastatic solid tumors The study has a dose escalation portion and a cohort expansion portion in Module A of the study. Combination therapy with pembrolizumab will occur in Module B of the study Participants will receive vobramitamab tavatecan by intravenous (IV) infusion. The dose of vobramitamab tavatecan will be assigned at the time of enrollment. Pembrolizumab will be administered at 200 mg every 3 weeks. Participants may receive up to 35 treatments if there are no severe side effects and as long as the cancer does not get worse. Participants will be monitored for side effects, and progression of cancer, have blood samples collected for routing laboratory work, and blood and tumor samples collected for research purposes.
Conditions
- Advanced Solid Tumor
- Advanced Cancer
- Metastatic Cancer
- Squamous Cell Carcinoma of Head and Neck
- Non Small Cell Lung Cancer
- Small-cell Lung Cancer
- Bladder Cancer
- Sarcoma
- Endometrial Cancer
- Melanoma
- Castration Resistant Prostatic Cancer
- Cervical Cancer
- Colorectal Cancer
- Gastric Cancer
- Gastro-esophageal Cancer
- Pancreas Cancer
- Clear Cell Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Platinum-resistant Ovarian Cancer
- Breast Cancer
- Ovarian Cancer
- Esophageal Squamous Cell Cancer (SCC)
Interventions
MGC026 Dose EscalationBiological
Escalating doses of MGC026
MGC026 Dose for ExpansionBiological
MGC026 recommended dose for expansion
PembrollizumabBiological
200 mg, IV, every 3 weeks.
vobramitamab tavatecanBiological
less than RDE dose level, IV, every 3 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) and serious AEs (SAEs), AEs leading to dose delay, AEs leading to dose reduction, AEs leading to treatment discontinuations, AEs meeting criteria for dose limiting toxicity, and AEs of special interest.Time frame: Throughout the study, up to 135 weeks
Locations
12 sites in 3 countries. Site status is shown where the registry gives one.
The Angeles Clinic and Research Institute
Los Angeles, California · Recruiting
START Midwest
Grand Rapids, Michigan · Recruiting
START-New York Long Island
Lake Success, New York · Recruiting
Providence Cancer Institute
Portland, Oregon · Recruiting
The University of Texas MD Anderson Cancer Center
Houston, Texas · Recruiting
University of Texas Health Science Center at Houston
Houston, Texas · Recruiting
START Mountain Region
West Valley City, Utah · Recruiting
ICON Cancer Centre Wesley
Auchenflower, Queensland, Australia · Recruiting
ICON Cancer Centre Kurralta Park
Kurralta Park, South Australia, Australia · Recruiting
Austin Health- Olivia Newton John Cancer Center
Heidelberg, Victoria, Australia · Recruiting
Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom · Recruiting
The Royal Marsden NHS Foundation Trust
Sutton, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.